PubRank

Hermann Katinger

Author PubWeight™ 161.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002 9.62
2 Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004 8.99
3 The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol 2002 7.82
4 Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003 6.68
5 The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002 6.11
6 Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005 5.68
7 Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004 5.29
8 Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005 4.26
9 Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005 2.86
10 Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 2005 2.50
11 Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004 2.47
12 The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 2004 2.02
13 Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007 1.81
14 Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol 2005 1.78
15 Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 2005 1.68
16 In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007 1.56
17 Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003 1.55
18 Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 2007 1.46
19 Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol 2003 1.45
20 Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology 2004 1.45
21 Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007 1.44
22 Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol 2004 1.44
23 Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 2006 1.43
24 Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 2004 1.40
25 hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol 2008 1.40
26 Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 2006 1.30
27 Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother 2006 1.27
28 Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004 1.24
29 Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 2009 1.21
30 In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 2007 1.20
31 Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 2002 1.17
32 The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv Exp Med Biol 2003 1.15
33 Interaction of U-box E3 ligase SNEV with PSMB4, the beta7 subunit of the 20 S proteasome. Biochem J 2005 1.14
34 Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol Immunol 2004 1.11
35 Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol 2003 1.10
36 Contributions of DNA interstrand cross-links to aging of cells and organisms. Nucleic Acids Res 2007 1.09
37 SNEV is an evolutionarily conserved splicing factor whose oligomerization is necessary for spliceosome assembly. Nucleic Acids Res 2005 1.08
38 HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 2005 1.08
39 Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 2005 1.08
40 Comparison of early passage, senescent and hTERT immortalized endothelial cells. Exp Cell Res 2005 1.07
41 Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol Bioeng 2006 1.07
42 SNEV overexpression extends the life span of human endothelial cells. Exp Cell Res 2006 1.06
43 Effect of increased expression of protein disulfide isomerase and heavy chain binding protein on antibody secretion in a recombinant CHO cell line. Biotechnol Prog 2005 1.03
44 Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol 2005 1.02
45 Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res 2004 1.01
46 Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5. Mol Immunol 2007 0.98
47 Specific effects of synthetic oligopeptides on cultured animal cells. Biotechnol Prog 2002 0.97
48 Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J 2007 0.97
49 Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology 2006 0.97
50 Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol 2006 0.97
51 MicroRNAs as targets for engineering of CHO cell factories. Trends Biotechnol 2008 0.97
52 Early embryonic lethality of mice lacking the essential protein SNEV. Mol Cell Biol 2007 0.97
53 Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol 2006 0.95
54 Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology 2003 0.95
55 Partial humanization and characterization of an anti-idiotypic antibody against monoclonal antibody 2F5, a potential HIV vaccine? AIDS Res Hum Retroviruses 2007 0.95
56 Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses 2003 0.93
57 Aging and the ubiquitinome: traditional and non-traditional functions of ubiquitin in aging cells and tissues. Exp Gerontol 2006 0.93
58 Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 2003 0.93
59 Process parameter shifting: Part II. Biphasic cultivation-A tool for enhancing the volumetric productivity of batch processes using Epo-Fc expressing CHO cells. Biotechnol Bioeng 2006 0.93
60 Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. AIDS 2002 0.93
61 Characterization of a trimeric MPER containing HIV-1 gp41 antigen. Virology 2009 0.92
62 Telomerase immortalized human amnion- and adipose-derived mesenchymal stem cells: maintenance of differentiation and immunomodulatory characteristics. Tissue Eng Part A 2009 0.91
63 Enhancement of monoclonal antibody production by lysine-containing peptides. Biotechnol Prog 2003 0.90
64 High level expression of a promising anti-idiotypic antibody fragment vaccine against HIV-1 in Pichia pastoris. J Biotechnol 2007 0.90
65 MdAP, a novel protein in apple, is associated with the major allergen Mal d 1. Gene 2003 0.89
66 The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen. J Immunol 2006 0.89
67 Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. J Virol 2004 0.89
68 Serum-free transfection of CHO cells with chemically defined transfection systems and investigation of their potential for transient and stable transfection. Cytotechnology 2009 0.88
69 The absence of effect of gene copy number and mRNA level on the amount of mAb secretion from mammalian cells. Appl Microbiol Biotechnol 2008 0.87
70 Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol 2008 0.86
71 GMP production of liposomes--a new industrial approach. J Liposome Res 2006 0.86
72 Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6. J Mol Biol 2008 0.86
73 Characterisation of recombinant CHO cell lines by investigation of protein productivities and genetic parameters. J Biotechnol 2006 0.85
74 Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. J Biol Chem 2009 0.85
75 Protein-free transfection of CHO host cells with an IgG-fusion protein: selection and characterization of stable high producers and comparison to conventionally transfected clones. Biotechnol Bioeng 2007 0.85
76 Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma. Eur J Cancer 2008 0.84
77 Bacterial expression and refolding of human trypsinogen. J Biotechnol 2004 0.84
78 Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J Antimicrob Chemother 2003 0.83
79 Optimization of recombinant protein expression level in Escherichia coli by flow cytometry and cell sorting. Biotechnol Bioeng 2002 0.83
80 Altering the surface properties of baculovirus Autographa californica NPV by insertional mutagenesis of the envelope protein gp64. Eur J Biochem 2002 0.82
81 Blom7alpha is a novel heterogeneous nuclear ribonucleoprotein K homology domain protein involved in pre-mRNA splicing that interacts with SNEVPrp19-Pso4. J Biol Chem 2009 0.82
82 Confocal microscopy of giant vesicles supports the absence of HIV-1 neutralizing 2F5 antibody reactivity to plasma membrane phospholipids. FEBS Lett 2010 0.81
83 Nuclear flow FISH: isolation of cell nuclei improves the determination of telomere lengths. Exp Gerontol 2005 0.81
84 Fruit cross-reactive allergens: a theme of uprising interest for consumers' health. Biofactors 2005 0.81
85 Evaluation of a genomics platform for cross-species transcriptome analysis of recombinant CHO cells. Biotechnol J 2006 0.80
86 Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005 0.80
87 Long-term stability of marker gene expression in Prunus subhirtella: a model fruit tree species. J Biotechnol 2006 0.80
88 Mapping of Malus domestica allergens by 2-D electrophoresis and IgE-reactivity. Electrophoresis 2007 0.80
89 Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expr Purif 2006 0.80
90 Experimental design for in vitro skin penetration study of liposomal superoxide dismutase. J Pharm Biomed Anal 2005 0.79
91 IgM characterization directly performed in crude culture supernatants by a new simple electrophoretic method. J Immunol Methods 2010 0.79
92 Identification of four IgE-reactive proteins in raspberry (Rubus ideaeus L.). Mol Nutr Food Res 2008 0.79
93 Enhanced protein loading into liposomes by the multiple crossflow injection technique. J Liposome Res 2002 0.79
94 One step membrane incorporation of viral antigens as a vaccine candidate against HIV. J Liposome Res 2007 0.79
95 Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. J Aerosol Med Pulm Drug Deliv 2008 0.79
96 The crossflow injection technique: an improvement of the ethanol injection method. J Liposome Res 2002 0.79
97 Identification of transgene integration loci of different highly expressing recombinant CHO cell lines by FISH. Cytotechnology 2006 0.79
98 Liposomes produced in a pilot scale: production, purification and efficiency aspects. Eur J Pharm Biopharm 2002 0.79
99 Long term stability of rh-Cu/Zn-superoxide dismutase (SOD)-liposomes prepared by the cross-flow injection technique following International Conference on Harmonisation (ICH)-guidelines. Eur J Pharm Biopharm 2002 0.78
100 Age-related alterations in the protein expression profile of C57BL/6J mouse pituitaries. Exp Gerontol 2002 0.78
101 Establishment of a strategy for the rapid generation of a monoclonal antibody against the human protein SNEV (hNMP200) by flow-cytometric cell sorting. J Immunol Methods 2005 0.78
102 Screening for improved cell performance: selection of subclones with altered production kinetics or improved stability by cell sorting. Biotechnol Bioeng 2004 0.78
103 Transcriptional profiling of phenotypically different Epo-Fc expressing CHO clones by cross-species microarray analysis. Biotechnol J 2008 0.78
104 Mapping of fruit allergens by 2D electrophoresis and immunodetection. Expert Rev Proteomics 2008 0.78
105 Large-scale production and characterization of novel CD4+ cytotoxic T cells with broad tumor specificity for immunotherapy. Mol Cancer Res 2009 0.77
106 A novel strategy for quantitative isoform detection directly performed from culture supernatant. J Pharm Biomed Anal 2006 0.77
107 Serum-free transfection of CHO-cells with tailor-made unilamellar vesicles. Cytotechnology 2007 0.77
108 Validated method for quantification of genetically modified organisms in samples of maize flour. J Agric Food Chem 2006 0.77
109 Applicability of different fluorescent dyes for isoform quantification on linear IPG gels. Electrophoresis 2007 0.77
110 Reepithelialization of experimental scalds effected by topically applied superoxide dismutase: controlled animal studies. Wound Repair Regen 2002 0.76
111 Screening and identification of putative allergens in berry fruits of the Rosaceae family: technical challenges. Biofactors 2008 0.76
112 Topological transformation of liposomes by a membrane-affecting domain of recombinant human erythropoietin. J Liposome Res 2010 0.75
113 On-line detection of microbial contaminations in animal cell reactor cultures using an electronic nose device. Cytotechnology 2005 0.75
114 Unsung hero Robert C. Gallo. Science 2009 0.75
115 Biotechnology of temperate fruit trees and grapevines. Acta Biochim Pol 2005 0.75
116 CHO-recombinant human growth hormone as a protease sensitive reporter protein. Appl Microbiol Biotechnol 2009 0.75
117 Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine. Mol Biotechnol 2008 0.75
118 Improvement of the energy metabolism of recombinant CHO cells by cell sorting for reduced mitochondrial membrane potential. J Biotechnol 2007 0.75
119 HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells. Biochem Biophys Res Commun 2007 0.75